Topics:
Thoracic Malignancies • Medical Oncology • Non-small cell lung cancer • EGFR+ • Targeted therapies
Do you consider using 160 mg osimertinib in patients with EGFR-positive metastatic NSCLC to the brain?
Answer from: Medical Oncologist at Academic Institution
The BLOOM study [Yang et al., PMID 31809241] was the first to address the question of CNS dosage for patients with EGFR mutant NSCLC with brain metastases. In this, patients with cytologically confirmed leptomeningeal (LM) disease received osimertinib 160 mg once daily. LM disease was assessed by bl...
Sign in or Register to read more